0.53
+0.0137(+2.68%)
Currency In USD
| Previous Close | 0.51 |
| Open | 0.51 |
| Day High | 0.54 |
| Day Low | 0.51 |
| 52-Week High | 1.74 |
| 52-Week Low | 0.34 |
| Volume | 969,192 |
| Average Volume | 957,671 |
| Market Cap | 45.25M |
| PE | -1.64 |
| EPS | -0.32 |
| Moving Average 50 Days | 0.54 |
| Moving Average 200 Days | 0.55 |
| Change | 0.01 |
If you invested $1000 in Century Therapeutics, Inc. (IPSC) since IPO date, it would be worth $23.03 as of December 04, 2025 at a share price of $0.526. Whereas If you bought $1000 worth of Century Therapeutics, Inc. (IPSC) shares 3 years ago, it would be worth $51.3 as of December 04, 2025 at a share price of $0.526.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Century Therapeutics to Participate in Piper Sandler 37th Annual Healthcare Conference
GlobeNewswire Inc.
Nov 25, 2025 9:01 PM GMT
PHILADELPHIA, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced
Century Therapeutics Announces New Beta Islet Program for Type 1 Diabetes
GlobeNewswire Inc.
Nov 13, 2025 12:00 PM GMT
Allo-Evasion™ 5.0-engineered iPSC beta islets are designed to overcome immune rejection and provide durable glucose control without chronic immunosuppressionCompelling preclinical data demonstrate rapid reversal of diabetes and sustained normoglycemi
Century Therapeutics to Present at Chardan’s 9th Annual Genetic Medicines Conference
GlobeNewswire Inc.
Oct 14, 2025 8:01 PM GMT
PHILADELPHIA, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), a biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies for autoimmune diseases and cancer, today announced